Last reviewed · How we verify
NCT06092606
A Multicenter Clinical Trial on DH001 Tablets in the Prevention of Doxorubicin-induced Cardiotoxicity in Cancer Patients
Phase 2 trial testing Control group:DH001 placebo in Cancer in 90 participants. Status unknown.
31 January 2025
Quick facts
| Lead sponsor | Monyan Pharmaceutical (Shanghai) Co., Ltd. |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | prevention |
| Enrollment | 90 |
| Start date | 4 April 2023 |
| Primary completion | 31 January 2025 |
| Estimated completion | 31 January 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Control group:DH001 placebo — full drug profile →
- Trial group: DH001 low-dose group — full drug profile →
- Trial group: DH001 high-dose group — full drug profile →
Conditions studied
- Cancer — all drugs for Cancer →
- Heart Failure — all drugs for Heart Failure →
- Arrhythmia — all drugs for Arrhythmia →
- Doxorubicin Induced Cardiomyopathy — all drugs for Doxorubicin Induced Cardiomyopathy →
Sponsor
Monyan Pharmaceutical (Shanghai) Co., Ltd. — full company profile →
Who can join
Adults 18 to 75, any sex, with Cancer or Heart Failure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Purpose：1. Preliminary evaluation of the preventive effect of DH001 on doxorubicin-induced cardiotoxicity in cancer patients 2.To explore appropriate dosages to provide basis for dosages in subsequent confirmatory studies 3.To evaluate the effect of DH001 on the efficacy of doxorubicin treatment in cancer patients 4.To evaluate the safety of DH001 in cancer patients treated with doxorubicin
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06092606
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cancer
Currently open trials in the same condition.
- NCT07390045 — Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors · NA · recruiting
- NCT07528547 — Hypersight and Ethos In Pediatric Radiotherapy · NA · recruiting
- NCT07481890 — Feasibility and Efficacy of the EMDR Toolbox Method in Cancer Patients. · NA · recruiting
- NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
- NCT07305740 — On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06092606 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Monyan Pharmaceutical (Shanghai) Co., Ltd.
- Last refreshed: 23 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06092606.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing